Document is current
Any future updates will be listed below
-
Authors
McDowell, Elliott H. https://orcid.org/0000-0002-0472-1441
Kennedy, Jason N. https://orcid.org/0000-0001-7604-899X
Feehan, Michael https://orcid.org/0000-0002-3921-1089
Bell, Stacey A. https://orcid.org/0000-0002-4523-1713
Marking, Sarah E. https://orcid.org/0009-0003-7538-5806
Zdinak, Jessica P. https://orcid.org/0009-0000-7963-728X
Joyce, Andrew R. https://orcid.org/0000-0001-7140-473X
Humphreys, Michelle https://orcid.org/0009-0008-2127-1279
-
Funding
Funding for this research was provided by:
Rogue Holdings LLC
- License Information
-
More Information
Article History
Received: 10 June 2024
Accepted: 18 October 2024
First Online: 22 November 2024
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Sterling Institutional Review Board in Atlanta, GA (Study ID 9741; Approved 28 February 2022). Electronic informed consent was obtained from all study participants prior to enrollment. This article was written to guidelines defined in the STROBE Statement and Good Publication Practices for Pharmaceutical Companies.
: Not applicable.
: EHM, MF, JNK, SAB, and MH were employed by Oracle Life Sciences, Oracle Corporation (formerly, Cerner Enviza) while conducting this research and drafting this manuscript. Oracle Life Sciences received funding from the Sponsor (Rogue Holdings, LLC) to conduct the research described in this manuscript and to cover publication costs. SEM and ARJ were employed by Consilium Sciences, a company that provides consulting services on a project basis to companies involved in tobacco harm reduction (including the Sponsor), while this research was conducted. JPZ was employed by Applied Research and Analysis Company, a company providing behavioral science research support to companies on a project basis (including the Sponsor), while this research was conducted. Otherwise, the study authors have no other conflicts of interest.
